Melanoma Vaccine Cuts Recurrence Risk After Surgery

Moderna and Merck’s personalized melanoma vaccine reduced the risk of cancer recurrence or death when added to pembrolizumab after surgery in a Phase 3 trial. The reported reduction was 42% relative to pembrolizumab alone. For people whose melanoma has been removed but remains at high risk of returning, that is a consequential result. It answers a carefully bounded question: what happens when an individualized vaccine joins an existing immunotherapy after an operation.

The vaccine, intismeran autogene, is made using information from each patient’s tumor. Its mRNA instructions are intended to help the immune system recognize features of that cancer; pembrolizumab, sold as Keytruda, blocks an immune checkpoint that can impede an attack. This is a therapeutic vaccine for people already diagnosed with melanoma, rather than a vaccine given to prevent melanoma in healthy people. Investigators tested the two treatments together because the personalized signal and the checkpoint inhibitor have complementary intended roles. The clinical result measures the combination’s effect, not the vaccine’s performance on its own.

What the Trial Measured

INTerpath-001 enrolled 1,137 people with stage IIB to IV cutaneous melanoma whose tumors had been completely removed. They had not previously received systemic cancer treatment. The randomized, double-blind trial assigned participants in a two-to-one ratio to intismeran plus pembrolizumab or pembrolizumab alone. The planned regimen involved up to nine vaccine doses, given every three weeks, alongside pembrolizumab given approximately every six weeks for about a year. Merck and Moderna, which are developing intismeran, reported that the study met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival.

Recurrence-free survival counts the time until melanoma returns anywhere, or the participant dies from any cause. The reported hazard ratio for that endpoint was 0.58, with a 95% confidence interval of 0.45 to 0.75. Put plainly, the 42% figure describes a relative reduction in the measured rate of recurrence or death over follow-up. It does not mean that 42% of patients were cured, or that an individual patient’s chance of recurrence fell by 42 percentage points.

The proportions give the relative figure a second perspective. After an average follow-up of 24.6 months, 82.2% of participants receiving the combination and 70% receiving pembrolizumab alone were reported to remain recurrence-free. The combination also reduced the trial’s risk measure for distant spread or death by a reported 38%. Those findings concern outcomes with direct consequences: melanoma that returns in a distant organ may require further treatment and can be harder to manage. Overall survival remains under follow-up, however, so the recurrence result cannot yet be read as proof that the combination helps people live longer.

Melanoma Institute Australia, whose medical director Georgina Long led the trial, described generally tolerable vaccine side effects including temporary injection-site pain, headache and chills, and said pembrolizumab side effects did not increase. That account comes from investigators involved in the study. Even a manageable additional treatment asks something of patients: repeated doses, time, and a manufacturing process that must begin with their own tumor. Safety and practicality belong in the same conversation as efficacy when the proposed treatment is an addition to an existing regimen.

Why This Result Changes the Question

The Phase 3 result follows an earlier signal rather than appearing from nowhere. In the Phase 2b KEYNOTE-942 study, Merck and Moderna reported a 49% relative reduction in recurrence or death for the same combination compared with pembrolizumab alone at five-year follow-up. INTerpath-001 has now found an advantage on the same primary outcome in a larger, blinded Phase 3 trial. That progression strengthens the case for the postsurgery combination beyond the earlier study, while leaving the reported Phase 2 and Phase 3 percentages as separate estimates. Their follow-up periods differ, and the Phase 3 trial included a broader range of recurrence risk. Subtracting one headline percentage from the other would make a comparison the trials were not designed to make.

The treatment landscape has also moved. For some patients with removable melanoma, clinicians increasingly use immunotherapy before surgery, an approach called neoadjuvant treatment. INTerpath-001 enrolled people after complete removal of their melanoma and compared two postsurgery regimens. Its result therefore helps answer whether adding intismeran improves on pembrolizumab alone in that sequence; it does not rank the combination against a strategy that starts immunotherapy before the operation. Melanoma specialists discussed that unresolved treatment-sequencing question. Which approach fits a patient also depends on circumstances the trial’s two arms were not built to compare.

That boundary leaves a useful, narrower prospect. If surgery has already happened and pembrolizumab is the relevant postsurgery comparator, INTerpath-001 offers evidence that adding the vaccine can keep more people free of recurrence during the measured period. The two decisions share a disease and an immune-based treatment, but they occur at different points in care. Treating them as interchangeable would give this vaccine credit for a contest it never entered.

There is a second transition between a successful trial and routine use: each course has to be made for one person. CNBC reported that custom manufacture can take roughly six weeks, during which patients can begin pembrolizumab. Marisol Soengas, a melanoma researcher who was not involved in INTerpath-001, raised questions about whether production can scale and remain affordable, in comments to SMC Spain carried by Wired. Those are implementation questions, not objections to the recurrence finding. A regimen can improve a trial endpoint and still face limits on how quickly, widely and affordably it can reach people.

Intismeran remains investigational and requires regulatory review before routine use. The strongest reading of INTerpath-001 is already substantial: a personalized vaccine added to pembrolizumab reduced recurrence or death in a defined group after melanoma surgery. The next decisions concern a different set of measurements: longer-term survival, the place of postsurgery treatment alongside preoperative options, and whether a vaccine made separately for every patient can be delivered at scale.